Reata Pharmaceuticals, Inc. announced the appointment of Geoffrey A. Block, M.D., as Vice President, Nephrology. Dr. Block, a world-renowned nephrologist, joins Reata with over 20 years of experience conducting clinical research and treating patients with chronic kidney disease (CKD). Dr. Block served as the Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver Nephrologists. Dr. Block has participated in multiple clinical studies of bardoxolone methyl (bardoxolone), Reata’s lead clinical candidate, and recently presented results from both the Phase 2 CARDINAL and Phase 2 PHOENIX trials of bardoxolone in rare forms of CKD at the American Society of Nephrology Kidney Week 2018.